Business Wire

FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device ...
The American Journal of Managed Care

Dr Jennifer Gass Provides an Overview of FCS' Next-Generation Sequencing Laboratory

Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation ...
Labroots

Break the ceiling: Elevate your oncology NGS testing with expert-curated data

When the Precision Medicine Initiative was launched in 2015, it completely transformed patient care in oncology. Now, individual differences in genetics, environment and lifestyle, along with the ...
Labroots

Beyond the noise: Identifying clinically relevant mutations in somatic NGS testing

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading ...